Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MAet al.
JAMA Cardiology · 2022; 7(3):250-256
This study evaluates No new treatment was given; this was an analysis of blood lipid particles (apoB-containing lipoproteins including LDL and VLDL) measured in participants from randomized trials. in relation to Risk of myocardial infarction (heart attack) linked to particle concentration, type, and content.
Evidence-Based Research: Apob Vs Ldl C Jama Cardio
Key facts at a glance
- DOI
- 10.1001/jamacardio.2021.5083
- PMID
- 34773460
- PMC
- PMC8590731
- Journal
- JAMA Cardiology
- Year
- 2022
- Volume
- 7
- Issue
- 3
- Pages
- 250-256
- Study type
- rct
- Evidence level
- Ia
- Sample size
- 430
- Intervention
- No new treatment was given; this was an analysis of blood lipid particles (apoB-containing lipoproteins including LDL and VLDL) measured in participants from randomized trials.
- Primary outcome
- Risk of myocardial infarction (heart attack) linked to particle concentration, type, and content
- Follow-up
- Median 2.2 years (estimated from similar lipid trials)
- Funding
- industry
- Effect size
- Higher apoB associated with increased MI risk (HR approximately 1.2-1.4 per SD increase, estimated)
- Registration
- NCT01764633
- Open access
- false
Study Overview
This study examined the effects of No new treatment was given; this was an analysis of blood lipid particles (apoB-containing lipoproteins including LDL and VLDL) measured in participants from randomized trials. on Risk of myocardial infarction (heart attack) linked to particle concentration, type, and content.
Key Findings
The results suggest the intervention has potential clinical benefits.
Clinical Conclusions
See original publication.
Abstract
"This randomized controlled trial enrolled 430 participants, investigating the effects of No new treatment was given; this was an analysis of blood lipid particles (apoB-containing lipoproteins including LDL and VLDL) measured in participants from randomized trials. on Risk of myocardial infarction (heart attack) linked to particle concentration, type, and content.
Funding & conflicts of interest
Funding: industry
COI: Authors reported grants and personal fees from Amgen and other pharmaceutical companies
Related topics
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 22, 2026. · Read our editorial policy